IFNG and melanoma: Since IFN-γ upregulates PD-L1/PD-L2 expression through JAK/STAT signaling [13], we first tested whether a JAK/STAT inhibitor ruxolitinib controlled the PD-L1/PD-L2 expression in human melanoma cells.